The post AAVE: Rise or Fall? January 15, 2026 Scenario Analysis appeared on BitcoinEthereumNews.com. AAVE is standing at a critical crossroads at the $172.44 levelThe post AAVE: Rise or Fall? January 15, 2026 Scenario Analysis appeared on BitcoinEthereumNews.com. AAVE is standing at a critical crossroads at the $172.44 level

AAVE: Rise or Fall? January 15, 2026 Scenario Analysis

AAVE is standing at a critical crossroads at the $172.44 level. While the overall uptrend continues, short-term bearish signals (MACD negative histogram, close below EMA20) make both scenarios possible. RSI at 50.33 is neutral, volume at $258.72M is stable, but the breakout direction will be decisive. Traders should be prepared for both directions: An upside breakout could trigger a rally, while a downside breakout could deepen the correction.

Current Market Situation

AAVE is trading at $172.44 with a %2.47 drop over the last 24 hours. The daily range is squeezed between $171.84 – $180.37, with volume at a moderate $258.72M level. Although the overall trend is uptrend, the short-term technical picture is mixed: RSI 50.33 in the neutral zone, MACD bearish (negative histogram expanding), price giving a bearish short-term signal below EMA20 ($173.22). Supertrend is in bearish mode and showing $186.32 resistance.

Multi-timeframe (MTF) analysis detects 14 strong levels in 1D/3D/1W: 2 supports/3 resistances in 1D, 1 support/4 resistances in 3D, 2 supports/5 resistances predominantly in 1W. Critical supports $165.85 (score 80/100) and $170.58 (68/100); resistances $173.38 (96/100) and $181.21 (70/100). Market news flow is calm, so technical levels will dominate. You can access detailed data from the AAVE Spot Analysis and AAVE Futures Analysis pages.

Scenario 1: Upside Scenario

How Does This Scenario Play Out?

The upside scenario is triggered by the price breaking above the $173.38 resistance (score 96/100) with strong volume. This level coincides with EMA20, and if a daily close occurs here, the short-term bearish momentum reverses. In the next step, momentum builds toward $181.21; if RSI stays sustainably above 50 and the MACD histogram turns positive, the uptrend continuation is confirmed. Supertrend flipping to bullish (above $186.32) provides additional confirmation. The scenario strengthens if supported by a volume increase (%20+), general recovery in the DeFi sector, or a drop in BTC dominance. If 1W resistances (5 levels) are overcome in MTF, it opens the door to a broader rally. In this scenario, invalidation is a daily close below $170.58 – if this level breaks, the upside probability is nullified.

Target Levels

First target $181.21 (medium-term resistance), followed by $186.32 Supertrend level. With strong momentum, $202.66 (score 28/100) becomes the main target – this aligns with 1W uptrend extension and Fibonacci 1.618 level. Risk/reward ratio (R/R), calculated with $170.58 stop-loss, is approximately 1:2.5 (assuming $172.44 entry). Traders can consider long positions on the $173.38 breakout, but always apply their own risk management.

Scenario 2: Downside Scenario

Risk Factors

The downside scenario begins with a close below the $170.58 support (score 68/100) – this is near the last 24h lows, and if accompanied by volume increase, bearish momentum accelerates. MACD negative histogram expands, RSI drops below 50, and price moves away from EMA20, solidifying the short-term bearish trend. Additional trigger: Break below $165.85 (score 80/100), which increases pressure due to excess resistance in MTF (total 12R vs 5S). General market correction (BTC below $90K), decrease in DeFi volume, or unexpected regulatory news heightens risk. If Supertrend remains bearish, $186.32 stays a distant dream. Invalidation: Daily close above $173.38 – if this happens, the downside scenario is invalidated.

Protection Levels

First protection $165.85, then $150.48 (score 44/100) as the main bearish target – this aligns with 1D/3D support extension and %12-15 correction. R/R around 1:2.8 with $173.38 stop-loss ($172.44 short entry). Traders can watch for short opportunities on the $170.58 breakout, keeping stop-losses tight.

Which Scenario to Watch?

Key triggers: For Bull: Close above $173.38 + volume increase + MACD positive crossover; For Bear: Close below $170.58 + RSI <45 + volume spike. Confirmation signals: 4H candle closes, OBV rise (bull) or fall (bear). MTF alignment is critical: 1D breakout should be supported by 3D/1W. With low volatility (ATR < %3), fakeout risk is high – wait. In every scenario, invalidation levels are clear: Below $170.58 for bull, above $173.38 for bear. Make your decision with your own analysis.

Conclusion and Monitoring Notes

AAVE at a crossroads: Uptrend potential is strong, but short-term pressures create balanced scenarios. Monitoring points: $173.38/$170.58 breakouts, MACD/RSI changes, volume profile. Weekly close (1W) determines direction – focus on Friday. Patience is key in a neutral market; early entries are risky. This analysis is for educational purposes and encourages your own research. Follow AAVE Spot and Futures pages for updates.

Crypto Research Analyst: Michael Roberts

Blockchain technology and DeFi focused

This analysis is not investment advice. Do your own research.

Source: https://en.coinotag.com/analysis/aave-rise-or-fall-january-15-2026-scenario-analysis

Market Opportunity
AaveToken Logo
AaveToken Price(AAVE)
$171.72
$171.72$171.72
-1.25%
USD
AaveToken (AAVE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26